Ranibizumab for Neovascularization in Sickle Cell Retinopathy

Withdrawn before enrolling · Not applicable

Conditions studied: Sickle Cell Anemia, Retinopathy

In brief

The purpose of this study is to determine the ocular and non-ocular safety of a single dose of ranibizumab in treating neovascularization secondary to sickle cell retinopathy.

Key facts

Study ID

NCT00618644

Run by

Kresge Eye Institute

People needed

0

Starts

2010-01-01

Expected to finish

2011-06-01

Last updated by the study team

2012-09-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with sickle cell anemia and retinopathy
• Over age 18 years
• Non-pregnant

You may not qualify if…

• Pregnant
• Glaucoma
• Patients using anticoagulants (e.g., warfarin)
• Retinal detachment

Where it is running

• Kresge Eye Institute — Detroit, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.